Safety and efficacy of cilostazol in the management of intermittent claudication

References

• AgrawalNKMaitiRDashD2007Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patientsPharmacol Res561182317548203
   PubMed Web of Science ®Google Scholar
• AhnYJeongMHJeongJW2008Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients – clilostazol for diabetic patients in drug-eluting stent (CIDES) trialCirc J7235918159096
   PubMed Web of Science ®Google Scholar
• AinsworthBEHaskellWLWhittMC2000Compendium of physical activities: an update of activity codes and MET intensitiesMed Sci Sports Exerc32SupplS49850410993420
   PubMed Web of Science ®Google Scholar
• AokiMMorishitaRHayashiS2001Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes modelDiabetologia4410344211484082
   PubMed Web of Science ®Google Scholar
• BeebeHGDawsonDLCutlerBS1999A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trialArch Intern Med15920415010510990
   PubMed Web of Science ®Google Scholar
• BramerSLForbesWPMallikaarjunS1999Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial diseaseClin Pharmacokinet37Suppl 211110702882
   PubMedGoogle Scholar
• BramerSLTataPNVMallikaarjunS1997Disposition of 14 C-cilostazol after single dose administration to healthy human subjectsPhar Res1411 SupplS612
   Google Scholar
• ChapmanTMGoaKL2003Cilostazol: a review of its use in intermittent claudicationAm J Cardiovasc Drugs31173814727939
   PubMedGoogle Scholar
• CleanthisMBhattacharyaVSmoutJ2005Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise induced platelet activationYearb Soc Acad Res Surg39
   Google Scholar
• DawsonDLCutlerBSMeissnerMH1998Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trialCirculation98678869715861
   PubMed Web of Science ®Google Scholar
• DawsonDLCutlerBSHiattWR2000A comparison of cilostazol and pentoxifylline for treating intermittent claudicationAm J Med1095233011063952
   PubMed Web of Science ®Google Scholar
• DouglasJSJrHolmesDRJrKereiakesDJ2005Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazolCirculation11228263216246948
   PubMed Web of Science ®Google Scholar
• ElamMBHeckmanJCrouseJR1998Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudicationArterioscler Thromb Vasc Biol18194279848888
   PubMed Web of Science ®Google Scholar
• GardnerAWPoehlmanET1995Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysisJAMA274975807674529
   PubMed Web of Science ®Google Scholar
• HashimotoAMiyakodaGHiroseY2006Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanismAtherosclerosis189350716545819
   PubMed Web of Science ®Google Scholar
• HayashiSMorishitaRMatsushitaH2000Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21Hypertension352374310642304
   PubMed Web of Science ®Google Scholar
• HiattWRWolfelEERegensteinerJG1992Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial diseaseJ Appl Physiol73346531506390
   PubMed Web of Science ®Google Scholar
• HiattWR2001Medical treatment of peripheral arterial disease and claudicationN Engl J Med34416082111372014
   PubMed Web of Science ®Google Scholar
• HiattWR2002Pharmacologic therapy for peripheral arterial disease and claudicationJ Vasc Surg3612839112469066
   PubMed Web of Science ®Google Scholar
• HiattWR2006The US experience with cilostazol in treating intermittent claudicationAtheroscler Suppl6213116275166
   PubMed Web of Science ®Google Scholar
• HiattWRNawazDBrassEP1987Carnitine metabolism during exercise in patients with peripheral vascular diseaseJ Appl Physiol62238373610932
   PubMed Web of Science ®Google Scholar
• IkedaYKikuchiMMurakamiH1987Comparison of the inhibitory effects of cilostazol, acetylsalicylic acid and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over studyArzneimittelforschung3756362956957
   PubMed Web of Science ®Google Scholar
• IshiiHKumadaYToriyamaT2008Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery diseaseClin J Am Soc Nephrol310344018322041
   PubMed Web of Science ®Google Scholar
• KumarMBhattacharyaV2007Cilostazol: a new drug in the treatment intermittent claudicationRecent Patents Cardiovasc Drug Discov21815
   PubMedGoogle Scholar
• LeeTMSuSFHwangJJ2001Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6Atherosclerosis158471611583728
   PubMed Web of Science ®Google Scholar
• LengGCFowlerBErnstEExercise for intermittent claudication. 2000Cochrane Database Syst Rev2CD00099010796572
   PubMedGoogle Scholar
• ManickavasagamSYeYLinY2007The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activationCardiovasc Drugs Ther213213017620005
   PubMed Web of Science ®Google Scholar
• MilaniRVLavieCJ2007The role of exercise training in peripheral arterial diseaseVasc Med12351818048473
   PubMed Web of Science ®Google Scholar
• MoneySRHerdJAIsaacsohnJL1998Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular diseaseJ Vasc Surg2726774discussion 274–5.9510281
   PubMed Web of Science ®Google Scholar
• PackerMCarverJRRodehefferRJ1991Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research GroupN Engl J Med3251468751944425
   PubMed Web of Science ®Google Scholar
• PrattCM2001Analysis of the cilostazol safety databaseAm J Cardiol8728D33D11137829
   PubMed Web of Science ®Google Scholar
• RegensteinerJGWareJEJrMcCarthyWJ2002Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trialsJ Am Geriatr Soc5019394612473004
   PubMed Web of Science ®Google Scholar
• StrandnessDEDalmanRPanianS1998Two doses of cilostazol versus placebo in the treatment of claudication: results of a randomized, multicenter trialCirculation9817 Suppl 11129665051
   PubMed Web of Science ®Google Scholar
• TakahashiSOidaKFujiwaraR1992Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in cultureJ Cardiovasc Pharmacol2090061282592
   PubMed Web of Science ®Google Scholar
• TamaiYTakamiHNakahataR1999Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatusHaemostasis292697610754379
   PubMedGoogle Scholar
• TaniTSakuraiKKimuraY1992Pharmacological manipulation of tissue cyclic AMP by inhibitors. Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cellsAdv Second Messenger Phosphoprotein Res25215271372812
   PubMedGoogle Scholar